Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL7250517 | 0.90 | LMNA (0.44) | PDE4DPDE4APDE4BPDE4CLMNA | |
| Ethylene SCHEMBL7249017 | 0.82 | LMNA (0.49) | PDE4DPDE4APDE4BPDE4CLMNA | |
| SCHEMBL7249855 | 0.81 | KDM4E (0.46) | PDE4DPDE4APDE4BPDE4CLMNA | |
| SCHEMBL7249854 | 0.81 | KDM4E (0.46) | PDE4DPDE4APDE4BPDE4CLMNA | |
| SCHEMBL7256680 | 0.80 | LMNA (0.45) | PDE4DPDE4APDE4BPDE4CLMNA | |
| SCHEMBL7256677 | 0.80 | LMNA (0.45) | PDE4DPDE4APDE4BPDE4CLMNA | |
| Ethylene SCHEMBL7250284 | 0.79 | PDE4D (0.45) | PDE4DPDE4APDE4BPDE4CLMNA | |
| SCHEMBL7256176 | 0.78 | LMNA (0.43) | PDE4DPDE4APDE4BPDE4CLMNA | |
| SCHEMBL7256179 | 0.78 | LMNA (0.43) | PDE4DPDE4APDE4BPDE4CLMNA | |
| SCHEMBL6607682 | 0.76 | PDE4D (0.46) | PDE4DPDE4APDE4BPDE4CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030100772-A1 | Oxygen-containing heterocyclic compounds | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-05-29 | — | — | US | disclosed |
| EP-1264829-A1 | OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100772-A1 | Oxygen-containing heterocyclic compounds | CBR1, CYP11B2, CBR3 | PDE4D 3430/4885PDE4A 2849/4885PDE4B 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.